The immune system's ability to recognize and eliminate cancer cells depends on tumor antigens—molecular markers that distinguish malignant cells from healthy tissue. These antigens determine whether the immune system can mount a precise, sustained attack without collateral damage. Glioblastoma Multiforme (GBM), one of the most aggressive cancers, produces few detectable antigens and actively evades immune surveillance, making it exceptionally difficult to treat. Targeting Survivin—a protein that is almost exclusively expressed in cancer cells—has emerged as a promising strategy to overcome this barrier.

I. Survivin: An Ideal Tumor Antigen Spanning Multiple Cancers

Survivin (also known as Baculoviral IAP Repeat Containing 5, BIRC5) is a protein that plays a critical role in inhibiting apoptosis and promoting cell proliferation. It is highly expressed in nearly all GBM cases—tricision's research shows expression in up to 93.88% of Chinese GBM patients[1]—and is also present across a wide range of malignancies, including gastric, bladder, prostate, lung, colorectal, pancreatic, breast, and ovarian cancers. Importantly, Survivin is virtually undetectable in normal adult tissues, making it an ideal target for precision immunotherapy with minimal off-tumor toxicity. Its expression levels are also closely correlated with tumor recurrence, drug resistance, and poor patient survival, further validating it as a clinically meaningful target.

II. The Intracellular Challenge: Why Conventional Approaches Fall Short

Most Tumor-Associated Antigens (TAAs), including Survivin, are located inside cancer cells—a compartment that is inaccessible to many popular immunotherapies such as Chimeric Antigen Receptor T Cells (CAR-T) and T-Cell Receptor-Engineered T Cells (TCR-T), which primarily recognize surface markers. The key to unlocking Survivin's potential lies in the fact that cancer cells break down intracellular proteins into peptide fragments and display them on the cell surface via Major Histocompatibility Complex Class I (MHC class I) molecules. CD8+ T cells can recognize these displayed fragments and destroy the presenting cells. Therefore, the goal is to develop vaccines that train the immune system to recognize and attack Survivin-derived peptides presented on MHC class I.

III. Dendritic Cell (DC) Vaccines: The Precision Engine for T Cell Activation

Dendritic Cells (DCs) are the immune system's most potent antigen-presenting cells—they act as both information processors and commanders of the adaptive immune response. Survivin-targeting mRNA-DC vaccines leverage this natural function through a three-step process:

• "Loading Intelligence": Messenger RNA (mRNA) encoding the full Survivin protein is introduced into DCs.
• "Processing Information": The DCs process Survivin into peptide fragments and display them on MHC class I molecules.
• "Precision Training": These antigen-loaded DCs are reinfused into the patient, where they activate and expand Survivin-specific CD8+ T cells that can seek out and destroy tumor cells expressing the antigen.

This approach elegantly overcomes the intracellular localization problem: the DCs act as a "translator" and "display case," exposing a hidden intracellular target to the immune system and enabling high-precision, low-collateral-damage anti-tumor activity.

IV. Global Landscape and tricision's Clinical Translation

International efforts have demonstrated the clinical promise of Survivin-targeted vaccines. For instance, the Phase IIa study of SurVaxM—a Survivin-targeting peptide vaccine developed in the United States—showed that when combined with chemotherapy, GBM patients achieved a median Overall Survival (OS) of nearly 26 months, significantly surpassing historical benchmarks[2]. SurVaxM has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and is being investigated in additional tumor types.

In China, tricision is leading the charge. Its "Survivin-Targeting DC Cell Injection" has entered clinical development and is designed specifically for the Chinese patient population, leveraging the high prevalence of Survivin expression across GBM and multiple solid tumors—including gastric, lung, and breast cancers. This positions the vaccine as a promising candidate for multi-cancer application.

From target discovery to technology translation, Survivin-targeting DC vaccines are opening a new therapeutic frontier for GBM and other malignancies. As research advances, the technology is expected to unlock its full potential across a broader spectrum of cancer types.

The Future is Within Reach: Beijing Tiantan Hospital is currently conducting a Phase I Clinical Trial (CT) of "Survivin-Targeting DC Cell Injection" in GBM patients (Clinical Trial Registration No.: CTR20240438). For inquiries, please contact: 15810449839, Manager Zhang.

References:

[1] A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme. Cancer Manag Res. 2019 Oct 17;11:8977-8989. doi: 10.21472

[2] Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023 Mar 1;41(7):1453-1465. doi: 10.1200/JCO.22.00996. Epub 2022 Dec 15. PMID: 36521103; PMCID: PMC9995096.

About the Survivin-Targeting mRNA-DC Tumor Vaccine

On January 10, 2023, tricision's mRNA-DC vaccine for GBM—Survivin-Targeting DC Cell Injection—received Clinical Trial Permission (CTP) from the National Medical Products Administration (NMPA) (Approval No. 2023LP00065), making it the world's first Survivin-targeting mRNA-DC therapeutic cancer vaccine to enter clinical trials.

The therapy involves extracting a patient's own DCs, loading them with mRNA encoding the Survivin antigen, and reinfusing them to induce antigen-specific CD4+ and CD8+ T cell responses. This approach is designed to eliminate residual tumor cells post-surgery, prevent recurrence, and extend survival in primary GBM patients.

Published data confirm the vaccine's efficacy: for glioma patients, median OS was 19 months in the treatment group (n=5) versus 11 months in the control group (n=28). For Small Cell Lung Cancer (SCLC) patients with brain metastases, the respective figures were 17 months (n=5) versus 7 months (n=13). One patient has been reported to have an OS exceeding 60 months (5 years), with no Dose-Limiting Toxicity (DLT) or treatment-related Adverse Events (AEs) observed across the entire cohort.